ACADIA Pharmaceuticals Inc
ACAD23.985USD
+0.455+1.93%
Horário de mercado （ET）Cotações atrasadas em 15 min
4.01BValor de mercado
17.51P/L TTM
Mais detalhes de ACADIA Pharmaceuticals Inc Empresa
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Informações da empresa
Código da empresaACAD
Nome da EmpresaACADIA Pharmaceuticals Inc
Data de listagemMay 27, 2004
CEOMs. Catherine Owen Adams
Número de funcionários653
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 27
Endereço12830 El Camino Real
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92130
Telefone18585582871
Sitehttps://acadia.com/
Código da empresaACAD
Data de listagemMay 27, 2004
CEOMs. Catherine Owen Adams
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Mr. Daniel B. (Dan) Soland
Mr. Daniel B. (Dan) Soland
Independent Director
Independent Director
44.04K
+27.09%
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Mr. Mark C. Schneyer
Mr. Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Edmund P. Harrigan
Dr. Edmund P. Harrigan
Independent Director
Independent Director
--
--
Mr. Thomas Andrew (Tom) Garner
Mr. Thomas Andrew (Tom) Garner
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Mr. Daniel B. (Dan) Soland
Mr. Daniel B. (Dan) Soland
Independent Director
Independent Director
44.04K
+27.09%
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q2
FY2023Q1
Por EmpresaUSD
Nome
Receita
Proporção
NUPLAZID
159.72M
65.37%
DAYBUE
84.60M
34.63%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
NUPLAZID
159.72M
65.37%
DAYBUE
84.60M
34.63%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
25.62%
BlackRock Institutional Trust Company, N.A.
11.22%
The Vanguard Group, Inc.
9.07%
RTW Investments L.P.
5.10%
State Street Global Advisors (US)
4.18%
Other
44.81%
Investidores
Investidores
Proporção
Baker Bros. Advisors LP
25.62%
BlackRock Institutional Trust Company, N.A.
11.22%
The Vanguard Group, Inc.
9.07%
RTW Investments L.P.
5.10%
State Street Global Advisors (US)
4.18%
Other
44.81%
Tipos de investidores
Investidores
Proporção
Investment Advisor
36.94%
Hedge Fund
36.72%
Investment Advisor/Hedge Fund
23.21%
Research Firm
4.68%
Pension Fund
1.03%
Sovereign Wealth Fund
0.88%
Individual Investor
0.58%
Bank and Trust
0.34%
Private Equity
0.28%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
668
175.40M
104.80%
-13.00M
2025Q1
688
177.74M
106.20%
-7.86M
2024Q4
643
167.35M
100.34%
-11.57M
2024Q3
599
161.17M
97.17%
-22.69M
2024Q2
603
166.04M
100.49%
-20.26M
2024Q1
612
167.37M
101.58%
-15.73M
2023Q4
589
164.89M
100.43%
-16.10M
2023Q3
560
161.37M
98.56%
-19.17M
2023Q2
557
164.35M
101.06%
-15.99M
2023Q1
589
162.49M
100.16%
-17.75M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Baker Bros. Advisors LP
42.88M
25.62%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.77M
11.22%
+8.64M
+85.36%
Mar 31, 2025
The Vanguard Group, Inc.
15.18M
9.07%
+1.26M
+9.02%
Mar 31, 2025
RTW Investments L.P.
8.54M
5.1%
-165.38K
-1.90%
Mar 31, 2025
State Street Global Advisors (US)
6.99M
4.18%
+2.47M
+54.68%
Mar 31, 2025
Point72 Asset Management, L.P.
4.65M
2.78%
+2.42M
+108.35%
Mar 31, 2025
Morgan Stanley & Co. LLC
4.26M
2.54%
-1.74M
-29.03%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.95M
1.77%
+77.40K
+2.69%
Mar 31, 2025
Fred Alger Management, LLC
2.77M
1.66%
+54.90K
+2.02%
Mar 31, 2025
Palo Alto Investors LP
2.66M
1.59%
-84.67K
-3.08%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Alger Weatherbie Enduring Growth ETF
4.69%
First Trust NYSE Arca Biotechnology Index Fund
4.65%
iShares Neuroscience and Healthcare ETF
4.3%
Invesco Biotechnology & Genome ETF
2.58%
ALPS Medical Breakthroughs ETF
2.44%
Tema Neuroscience and Mental Health ETF
2.36%
Virtus LifeSci Biotech Products ETF
1.91%
Invesco S&P SmallCap Health Care ETF
1.91%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.82%
Invesco Dorsey Wright Healthcare Momentum ETF
1.58%
Ver Mais
Alger Weatherbie Enduring Growth ETF
Proporção4.69%
First Trust NYSE Arca Biotechnology Index Fund
Proporção4.65%
iShares Neuroscience and Healthcare ETF
Proporção4.3%
Invesco Biotechnology & Genome ETF
Proporção2.58%
ALPS Medical Breakthroughs ETF
Proporção2.44%
Tema Neuroscience and Mental Health ETF
Proporção2.36%
Virtus LifeSci Biotech Products ETF
Proporção1.91%
Invesco S&P SmallCap Health Care ETF
Proporção1.91%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção1.82%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.58%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
